Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.95 EUR
Change Today +0.052 / 0.88%
Volume 0.0
LMW On Other Exchanges
As of 4:59 AM 11/26/15 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (LMW) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/15/15 - €7.99
52 Week Low
10/1/15 - €2.97
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for XENOPORT INC (LMW)

xenoport inc (LMW) Related Businessweek News

No Related Businessweek News Found

xenoport inc (LMW) Details

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders. It offers HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is in Phase I clinical trials for the treatment of psoriasis and relapsing forms of multiple sclerosis. In addition, it is developing arbaclofen placarbil product that is in Phase III clinical trials used for the treatment of spasticity in multiple sclerosis; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease has completed Phase II clinical trials. The company has a license agreement with Indivior PLC to develop and commercialize pharmaceutical products containing arbaclofen placarbil; license agreement with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan; and collaboration agreement with Glaxo Group Limited to develop and commercialize gabapentin enacarbil. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

152 Employees
Last Reported Date: 02/27/15
Founded in 1999

xenoport inc (LMW) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $439.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $380.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $364.2K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $346.1K
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2014.

xenoport inc (LMW) Key Developments

Xenoport, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Revised Net Product Sales of Horizant Guidance for the Full Year of 2015

Xenoport, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, total revenues were $11,393,000 against $31,068,000 a year ago. Loss from operations was $23,207,000 against income from operations of $8,312,000 a year ago. Net loss was $24,064,000 against net income of $8,259,000 a year ago. Basic and diluted net loss per share was $0.38 against basic and diluted net income per share of $0.13 a year ago. Total revenues were $11.4 million compared to $31.1 million for the same period in 2014. The decrease in total revenues for the quarter is primarily due to the recognition off $25 million in collaboration revenue resulting from the Indiviour license agreement in 2014, partially offset by increased HORIZANT net product sales, which increased to $11 million for the third quarter compared to $5.6 million for the same period in 2014. For the nine months, total revenues were $27,081,000 against $39,777,000 a year ago. Loss from operations was $66,731,000 against $31,504,000 a year ago. Net loss was $68,954,000 against $31,676,000 a year ago. Basic and diluted net loss per share was $1.10 against $0.52 a year ago. Based on actual results for the nine months ended September 30, 2015 and current trends, the company expects full-year net product sales of HORIZANT to come in at the lower end of the previously-established guidance range of $39 million to $43 million.

Xenoport, Inc. to Report Q3, 2015 Results on Nov 04, 2015

Xenoport, Inc. announced that they will report Q3, 2015 results at 4:30 PM, US Eastern Standard Time on Nov 04, 2015

Xenoport, Inc., Q3 2015 Earnings Call, Nov 04, 2015

Xenoport, Inc., Q3 2015 Earnings Call, Nov 04, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMW:GR €5.95 EUR +0.052

LMW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $4.68 USD +0.16
Alkermes PLC $74.06 USD -0.20
Skyepharma PLC 320.25 GBp +8.25
Teva Pharmaceutical Industries Ltd $63.00 USD +0.65
Valeant Pharmaceuticals International Inc C$115.35 CAD -1.01
View Industry Companies

Industry Analysis


Industry Average

Valuation LMW Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.9x
Price/Book 13.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact XENOPORT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at